What is the treatment approach for Nephrotic Syndrome (NS) vs Nephritic Syndrome (NeS) in pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment Approach for Nephrotic Syndrome vs Nephritic Syndrome in Pediatric Patients

Critical Distinction: These Are Different Diseases Requiring Completely Different Management

Nephrotic syndrome and nephritic syndrome are fundamentally different glomerular diseases with opposing treatment strategies—nephrotic syndrome is treated primarily with corticosteroids, while nephritic syndrome (acute post-infectious glomerulonephritis) is managed supportively without immunosuppression.


Nephrotic Syndrome Treatment

Initial Presentation (<12 years, no syndromic features)

Start oral prednisone 60 mg/m²/day or 2 mg/kg/day (maximum 60 mg/day) as a single morning dose for 4-6 weeks, followed by alternate-day prednisone 40 mg/m² for 2-5 months. 1, 2

  • Total treatment duration should be 8-12 weeks minimum (either 4 weeks daily + 4 weeks alternate-day OR 6 weeks daily + 6 weeks alternate-day) 1
  • Longer initial courses up to 6 months reduce relapse risk 1, 2
  • Approximately 80-94% of children will achieve remission with this regimen 3, 4

Children >12 Years or With Syndromic Features

Perform kidney biopsy and/or genetic testing before initiating corticosteroids and refer to specialty center. 1

  • Children <1 year likely have genetic causes and should not receive standard corticosteroid regimens 2
  • Syndromic features include skeletal abnormalities, neurodevelopmental delays, deafness, genital ambiguity, or facial dysmorphisms 1

Relapse Management

For infrequent relapses: Treat with prednisone 60 mg/m²/day until 3 consecutive days of remission, then switch to alternate-day prednisone 40 mg/m² for 4 weeks. 1, 2

  • Relapse defined as ≥3+ protein on dipstick for 3 consecutive days 2
  • Remission defined as urine protein <1+ on dipstick for 3 consecutive days 2

Frequent Relapses or Steroid-Dependent Disease

For children with frequent relapses who develop serious glucocorticoid toxicity or all children with steroid-dependent nephrotic syndrome, prescribe glucocorticoid-sparing agents rather than continuing corticosteroids alone. 1

The 2025 KDIGO guidelines eliminate the distinction between "first-line" and "alternative" agents 1:

  • For frequently relapsing disease: Cyclophosphamide (2 mg/kg/day for 8-12 weeks) or levamisole (2.5 mg/kg alternate days) are preferable 1
  • For steroid-dependent disease: Mycophenolate mofetil, rituximab, calcineurin inhibitors (cyclosporine/tacrolimus), or cyclophosphamide are preferable 1
  • Patients should be in remission with glucocorticoids before starting these agents, with glucocorticoids continued for 2 weeks after initiation 1

Steroid-Resistant Nephrotic Syndrome

Use cyclosporine or tacrolimus as initial second-line therapy for steroid-resistant disease. 1

  • Rituximab may achieve remission in approximately 30% of children with calcineurin inhibitor-resistant disease 1

Important Practice Changes from 2025 Guidelines

Do NOT routinely give daily glucocorticoids during upper respiratory tract infections to prevent relapses in children with frequently relapsing or steroid-dependent disease. 1

  • The PREDNOS2 study showed no benefit of prophylactic steroids during infections 1
  • Exception: May consider 3 extra doses of low-dose prednisone (0.5 mg/kg/day) in children already on alternate-day therapy with history of repeated infection-associated relapses 1

Nephritic Syndrome Treatment

Acute Post-Infectious Glomerulonephritis (Classic Nephritic Syndrome)

Nephritic syndrome requires supportive care only—do NOT use corticosteroids or immunosuppression.

The management is fundamentally different from nephrotic syndrome:

  • Fluid and sodium restriction for edema and hypertension
  • Antihypertensive therapy (typically loop diuretics, calcium channel blockers, or ACE inhibitors) for blood pressure control
  • Monitor for complications: Acute kidney injury, severe hypertension, pulmonary edema, hyperkalemia
  • Antibiotics only if active streptococcal infection is documented (penicillin for 10 days)
  • Self-limited disease: Most children recover completely within 2-4 weeks without immunosuppression

Key Distinguishing Features

Feature Nephrotic Syndrome Nephritic Syndrome
Proteinuria Massive (>40 mg/m²/hr) Mild-moderate
Hematuria Microscopic or absent Gross hematuria common
Edema Severe, generalized Mild, periorbital
Hypertension Uncommon Common
Complement (C3) Normal Low
Treatment Corticosteroids Supportive only

Critical Pitfalls to Avoid

  • Never treat nephritic syndrome with corticosteroids—this is a post-infectious process requiring supportive care only
  • Never discontinue steroids abruptly in nephrotic syndrome—increases relapse risk 2, 5
  • Never use standard corticosteroid regimens in children <1 year without genetic testing—they likely have genetic forms 2
  • Never continue corticosteroids alone in steroid-dependent disease—glucocorticoid-sparing agents are mandatory 1
  • Never assume FSGS on biopsy means steroid resistance—19% of white children with FSGS respond to corticosteroids 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Initial Treatment for Nephrotic Syndrome in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Corticosteroid Dosing and Administration in Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.